AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Management Patterns After Elevated Lipoprotein(a) Detection in a Predominantly Hispanic Safety-Net FQHC

By Ochoa Prieto M, Perez Pinzon J

Background: Lipoprotein(a) [Lp(a)] is an established risk factor for atherosclerotic cardiovascular disease (ASCVD), with approximately 90% of levels genetically determined. Although recent guidelines recommend universal one-time screening in adults, testing practices and optimal management strategies continue to remain elusive. Methods: Fair Haven Community Health Care is one of 20 community health centers participating in the American Heart Association’s Lp(a) Community Health Centers Discovery Project, a national initiative to drive awareness and shared decision-making around Lp(a) testing and cardiovascular disease risk management. From January to May 2026, we conducted a multi-cycle quality improvement initiative using Plan-Do-Study-Act (PDSA) cycles. We identified all adult patients who underwent Lp(a) screening, and patients with elevated levels, defined as >125 nmol/L, were included in the analysis. We evaluated downstream clinical outcomes and management changes following results. Results: We identified 94 patients with elevated Lp(a), with a mean level of 208 ± 90 nmol/L. Spanish was the preferred language for 58% of patients and English for 40%. Overall, 17% were uninsured, 29% had Medicaid, 25% had Medicare, and 20% had private insurance. Providers reviewed results in 86.2% of cases and communicated them to patients in 68%, yet only 66% of all patients (n = 62) underwent any management change, including lifestyle counseling alone in 56% and medication changes in 43%. Intervention rates did not differ significantly by insurance type or preferred language (p > 0.05). When stratifying Lp(a) values by tiers (125-149 nmol/L, 150-192 nmol/L and 193 nmol/L), overall intervention rates were similar (p = 0.66). In contrast, rates of cascade testing counseling differed significantly by Lp(a) tier, with patients with very high-risk values >193 nmol/L (n=35) being the most counseled at 60% (p=0.016). Among those with documented family history of ASCVD (n = 17), 65% received cascade testing counseling, with no significant difference compared with those without (p = 0.08). Among patients with established ASCVD, 91% underwent a medication change versus 65% of those without ASCVD, but this difference was not statistically significant (p = 0.07). In 39% of patients, no medication changes were made because LDL cholesterol levels were already at goal. Conclusions: Management of elevated Lp(a) remains challenging, with non-standardized clinical practices and substantial gaps in care, even among patients with very high-risk Lp(a) levels and established ASCVD. *Novartis Pharmaceuticals Corporation is proud to support the American Heart Association’s Lp(a) Community Health Centers Discovery Project.

doi.org/10.1161/circ.154.suppl_1.17522Interventions

AgingResearch.News